Sucampo Pharmaceuticals Appoints Alex Driggs as General Counsel
September 20 2017 - 4:15PM
Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global
biopharmaceutical company, today announced the appointment of Alex
Driggs to General Counsel and Corporate Secretary. Mr. Driggs
joined Sucampo in May 2015 as Associate General Counsel, was
appointed its Deputy General Counsel in September 2015, and has
most recently served as Acting General Counsel and Corporate
Secretary since June 2017.
Prior to joining Sucampo, from January 2013 through May 2015,
Mr. Driggs was an independent legal consultant for biotechnology
clients. From March until December 2012, Mr. Driggs served as
Senior Counsel in Amgen Inc.’s Licensing & Alliance Management
Group. From 2009 until 2012, Mr. Driggs was the Associate General
Counsel for Micromet, Inc., a public biotechnology company that
developed blinatumomab and other innovative antibody products. Mr.
Driggs began his legal career at Cooley LLP as an associate in the
Life Sciences and Technology Transactions groups.
“Alex has extensive experience advising biotechnology and life
sciences companies, and he has become an integral part of the
Sucampo team in recent years,” said Peter Greenleaf, Chief
Executive Officer of Sucampo. “He has a proven track record of
offering expert legal counsel to our management and board of
directors and we look forward to Alex’s increasingly important role
as we advance our strategy to grow and advance our late-stage
pipeline in highly specialized areas of significant unmet medical
need.”
Mr. Driggs received his law degree from New York
University School of Law and his undergraduate degree in Philosophy
from Harvard University. He is a member of the Virginia State
Bar.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of highly specialized medicines. Sucampo has a
late-stage pipeline of product candidates in clinical development
for orphan disease areas, including VTS-270, a mixture of
2-hydroxypropyl-B-cyclodextrins with a specific compositional
fingerprint that has been granted orphan designation in the U.S.
and Europe and is in a pivotal Phase 2/3 clinical trial for the
treatment of Niemann-Pick Disease Type C-1, a rare progressive
genetic disorder. VTS-270 has also been granted breakthrough
therapy designation in the U.S. Sucampo has an exclusive option for
the North American rights to CPP-1X/sulindac, which is in Phase 3
development for the treatment of familial adenomatous polyposis and
has been granted orphan drug designation in the U.S. The company
has two marketed products – AMITIZA and RESCULA. For more
information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).
Twitter LinkedIn
Contact:Sucampo Pharmaceuticals, Inc.Silvia
TaylorSenior Vice President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Sep 2023 to Sep 2024